FDA Aims Neglected Tropical Disease Guidance At Inexperienced Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
You may also be interested in...
FDA Cuts Priority Review Voucher Fee By 32%; No Takers For FY 2013
By taking into account the incremental costs of priority review and eliminating the IND aspect of the calculation, the agency reduces the fee to redeem a tropical disease priority review voucher to $3.6 million in fiscal year 2013.
Tropical Disease Development Partnerships Want More Help From FDA
The agency’s infrastructure is not attracting many of the Product Development Partnership sponsors, Aeras official says, but new draft guidance could help.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.